NCT06231563View on ClinicalTrials.gov

Ketamine for Veterans With Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Parkinson's Disease
Interventions
DRUG

Ketamine

intravenous ketamine infusion 0.5 mg/kg

DRUG

Remimazolam

intravenous remimazolam infusion 0.25 mg/kg

Trial Locations (1)

94121-1563

RECRUITING

San Francisco VA Medical Center, San Francisco, CA, San Francisco

All Listed Sponsors
lead

VA Office of Research and Development

FED